---
title: "HTFL HeartFlow"
canonical: "https://supercyclehq.com/stock/heartflow"
type: "stock"
dataAsOf: "2026-11-02"
ticker: "HTFL"
license: "Free to use and quote with attribution to supercyclehq.com. Do not redistribute as a dataset."
disclaimer: "Informational only, not investment advice. The AI Exposure Score is Supercycle's editorial opinion. Agent portfolios are simulated paper portfolios run by AI."
---

# HeartFlow (HTFL)

HeartFlow uses AI to diagnose heart disease from standard CT scans.

## AI Exposure Score

**94/100, Pure Play.** Revenue is entirely fees for AI generated coronary analyses; the business would not exist without its models. The thesis depends on reimbursement, guideline adoption, and clinician trust rather than AI infrastructure spending.

## Quote

| Field | Value |
| --- | --- |
| Price (EOD close) | $54.49 |
| Change 1d | -7.72% |
| Change 7d | -4.41% |
| Change 30d | +10.48% |
| Change 1y | +60.05% |
| 52-week high | $60.53 |
| 52-week low | $20.49 |
| Market cap | $4.7B |
| P/E | n/a |
| EPS | $-0.24 |
| Next earnings | 2026-11-12 |

Quote as of 2026-11-02.

## Company

| Field | Value |
| --- | --- |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Headquarters | San Francisco, CA |
| CEO | John C.M. Farquhar |
| Employees | 843 |
| Website | https://www.heartflow.com |
| Buildout layers | [AI Healthcare](https://supercyclehq.com/category/ai-healthcare) |

## What the company does

HeartFlow uses AI to diagnose heart disease from standard CT scans. The company's software builds a personalized 3D model of a patient's coronary arteries and computes how blood flows through them, giving cardiologists answers that once required invasive catheterization. It earns revenue from per case analysis fees billed when clinicians order its tests.

Its product line covers the FFRct Analysis for blood flow assessment, Plaque Analysis for AI measured plaque burden, and Roadmap Analysis for coronary anatomy, together forming a precision coronary care platform used across hospital networks in the United States and internationally.

Founded in 2007 out of research at Stanford, HeartFlow is headquartered in San Francisco, employs around 840 people, and trades on the NASDAQ. Its technology is supported by clinical guidelines and a growing body of published outcome studies.

## Role in the AI buildout

HeartFlow sits in the AI Healthcare layer, where trained models generate revenue directly as diagnostic output. Each analysis is inference: a CT scan goes in, an AI computed physiologic assessment comes out, and HeartFlow bills for it. That makes the company a clean test of AI economics in medicine, with automation replacing manual processing over time. The thesis depends on reimbursement, guideline adoption, and clinician trust rather than on AI infrastructure spending.

## FAQ

### What does HeartFlow do?

HeartFlow analyzes coronary CT scans with AI to diagnose coronary artery disease. Its software constructs a 3D model of a patient's arteries and simulates blood flow, helping cardiologists decide whether a patient needs intervention without an invasive diagnostic procedure. Hospitals pay per analysis.

### How is HeartFlow exposed to AI?

Entirely. Revenue comes from fees for AI generated analyses, and the product could not exist without its models. Supercycle rates it Pure Play with an AI Exposure Score of 94 out of 100, among the clearest medical AI pure plays on public markets.

### Is HTFL a pure play AI stock?

Yes. Every product, FFRct Analysis, Plaque Analysis, and Roadmap Analysis, is the direct output of AI models applied to imaging data. There is no hardware, device, or non-AI service line, placing HeartFlow firmly in Supercycle's Pure Play tier.

### What is FFRct?

FFRct stands for fractional flow reserve derived from CT. HeartFlow's software computes this measure of how severely a blockage limits blood flow, using computational fluid dynamics and AI on a standard CT scan, a value that previously required a pressure wire inside the artery.

### Who leads HeartFlow?

John Farquhar serves as chief executive. The company was founded in 2007 out of Stanford research by Charles Taylor and John Stevens, who developed the computational modeling of coronary blood flow that became the company's diagnostic platform.

---

Source: https://supercyclehq.com/stock/heartflow. Data as of 2026-11-02. Prices are end-of-day closes, never live.

Informational only, not investment advice. The AI Exposure Score is Supercycle's editorial opinion. Agent portfolios are simulated paper portfolios run by AI.

Free to use and quote with attribution to supercyclehq.com. Do not redistribute as a dataset.